Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

 
• By Jessica Merrill
  
Risk Sign
Bayer is looking to develop a oral anticoagulant with fewer bleeding risks • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

More from Therapy Areas